Virus therapy for bladder cancer

References 

1. American Cancer Society . Facts and figures 2007. Atlanta, GA: American Cancer Society; 2007;
2. Lamm DL, Blumenstein BA, Crawford ED, Montie JE, Scardino P, Grossman HB, et al. A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder. NEJM. 1991;325:1205–1209
3. O’Donnell MA, Boehle A. Treatment options for BCG failures. World J Urol. 2006;24:481–487
   • MEDLINE
   • CrossRef
4. Steinberg G, Bahnson R, Brosman S, Middleton R, Wajsman Z, Wehle M. Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group. J Urol. 2000;163:761–767
   • Abstract
   • Full Text
   • Full-Text PDF (76 KB)
   • CrossRef
5. Gomella LG, Mastrangelo MJ, McCue PA, Maguire HC, Mulholland SG, Lattime EC. Phase 1 study of intravesical vaccinia virus as a vector for gene therapy of bladder cancer. J Urol. 2001;166(October (4)):1291–1295
   • Abstract
   • Full Text
   • Full-Text PDF (1545 KB)
   • CrossRef
6. Pagliaro LC, Keyhani A, Williams D, Woods D, Liu B, Perrotte P, et al. Repeated intravesical instillations of an adenoviral vector in patients with locally advanced bladder cancer: a phase I study of p53 gene therapy. J Clin Oncol. 2003;21(June (12)):2247–2253
   • MEDLINE
   • CrossRef
7. Kuball J, Wen SF, Leissner J, Atkins D, Meinhardt P, Quijano E, et al. Successful adenovirus-mediated wild-type p53 gene transfer in patients with bladder cancer by intravesical vector instillation. J Clin Oncol. 2002;20(February (4)):957–965
   • MEDLINE
   • CrossRef
8. McKiernan J, Lamm D, Meng M, Nemunaitis J, Arseneau J, Stephenson J, et al. Abstract: Phase 1 Study of Single and Multi-Dose Administration of Intravesical CG0070 in Patients with Non-Muscle Invasive Bladder Cancer (NMIBC). In: Fifth International Meeting on Replicating Oncolytic Virus Therapeutics. Bannf, Canada. 2009;